The five stages of chronic kidney disease (CKD) indicate how well the kidneys are working, ranging from stage 1 (mild kidney ...

There used to be no specific treatments for heart failure with preserved ejection fraction, but recent clinical trials show ...

An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...

Use of finerenone for heart failure with preserved ejection fraction carries a hyperkalemia risk, especially in patients with kidney disease.

The deaths are also partly the result of medical successes: People are living longer, and more people are surviving heart ...

More than 830 million people worldwide have diabetes—a chronic, debilitating disease. But experts say it’s possible to ...

Some of the common risk factors for kidney disease include living with diabetes, high blood pressure or having a family ...

Sotagliflozin, a dual SGLT1/2 inhibitor, reduces cardiovascular events in people with diabetic kidney disease — ischemic ...

In patients with type 2 diabetes, the risk for chronic kidney disease differed among users of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylurea.

Given the rise in such cases in India, THE WEEK spoke to four patients to discuss the impact chronic kidney disease has had ...

SGLT2 inhibitors reduce the risk of kidney failure in patients with Type 2 diabetes and advanced chronic kidney disease, ...

Both chronic conditions are associated with ... and SGLT1 receptors by sotagliflozin reduces the risk of heart failure, kidney disease progression, heart attacks, and strokes.